—
C+
C+ The full Closelooknet — membership. Open the C+ overview

UCB SA (UCB.BR) — Technical state

As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 64 out of 100 (momentum 72 · quality 71 · valuation 44), as of 2026-11-03.
  • Signal: Recovery attempt under the 200-day — Trades +26.6% vs the 50-day and +15% vs the 200-day average, 3.5% below the 52-week high and +40.8% off the 52-week low; a death cross printed 60 sessions ago. Computed from daily closes. (as of 2026-11-02)
  • Trend: UCB SA trades 26.6% above its 50-day and 15.0% above its 200-day moving average. (as of 2026-11-02)

UCB is a biopharmaceutical company based in Brussels that develops medicines for neurology and immunology conditions. Its portfolio includes treatments for epilepsy, Parkinson's disease, psoriasis and related immune disorders, alongside allergy remedies and newer drugs aimed at rare neurological and autoimmune diseases.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the UCB.BR overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Recovery attempt under the 200-day

Trades +26.6% vs the 50-day and +15% vs the 200-day average, 3.5% below the 52-week high and +40.8% off the 52-week low; a death cross printed 60 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the UCB.BR chart & overview · quality & forensics · the signal board

FAQ · from the current data · as of 2026-11-02

Quick answers

What is the current Closelooknet signal on UCB.BR?

Recovery attempt under the 200-day — Trades +26.6% vs the 50-day and +15% vs the 200-day average, 3.5% below the 52-week high and +40.8% off the 52-week low; a death cross printed 60 sessions ago. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is UCB.BR above its 50-day and 200-day moving averages?

As of 2026-11-02, UCB SA trades +26.6% above its 50-day and +15% above its 200-day average, with the 20-day +19.8% away.

How far is UCB.BR from its 52-week high?

3.5% below the 52-week high and 40.8% above the 52-week low, as of 2026-11-02.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.